Ratings Modulight Oyj

Equities

MODU

FI4000511506

Market Closed - Nasdaq Helsinki Other stock markets 17:00:00 28/06/2024 BST			5-day change	1st Jan Change
1.22 ^EUR	+2.52%		-3.17%	+3.92%

04-29	Transcript : Modulight Oyj, Q1 2024 Earnings Call, Apr 29, 2024
04-27	Modulight Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MODULIGHT OYJ	+3.92%	55.64M		-
EL.EN. S.P.A.	-3.18%	810M		B+
SISRAM MEDICAL LTD	-31.56%	216M		-
LAMEDITECH CO., LTD.	0.00%	121M	-	-
LASEROPTEK CO., LTD.	-26.78%	84.74M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes